X
Alexion hastens review of successor to rare disease blockbuster Soliris
https://pharmaphorum.com/news/alexion-hastens-review-of-successor-to-rare-disease-blockbuster-soliris/
Alexion
Alexion’s Soliris successor aces two phase 3 trials
But Alexion shares hit by EU patent ruling
Alexion bids $855m for rare disease biotech Wilson Therapeutics
Wilson’s board has unanimously accepted the offer
Alexion to file successor to rare diseases drug Soliris
New drug is in patient-friendly subcutaneous form
Alexion cuts ties with Moderna and re-focuses
Alexion cuts collaborations with Moderna Therapeutics, Blueprint Medicines and Arbutus Biopharma
NHS supremo hails Alexion and Roche deals, but defends budget controls
Simon Stevens hails success in negotiating with pharma companies on price and data, and has defended NHS England’s record in promoting innovative medicines.
Alexion price cut opens up Strensiq to more patients
Managed access scheme will control costs to NHS.
